Neoadjuvant Imatinib for Locally Advanced GIST
Author Information
Author(s): Blesius Aurore, Cassier Philippe A, Bertucci François, Fayette Jerome, Ray-Coquard Isabelle, Bui Binh, Adenis Antoine, Rios Maria, Cupissol Didier, Pérol David, Blay Jean-Yves, Le Cesne Axel
Primary Institution: Institut Gustave Roussy
Hypothesis
What is the outcome of neoadjuvant imatinib treatment followed by surgery in patients with locally advanced non-metastatic GIST?
Conclusion
Neoadjuvant imatinib treatment followed by surgery significantly improves progression-free and overall survival in patients with locally advanced non-metastatic GIST.
Supporting Evidence
- 60% of patients had a partial response to imatinib.
- 36% of patients underwent surgical resection after treatment.
- Median progression-free survival was significantly longer for patients who underwent surgery.
Takeaway
Doctors gave medicine to help shrink tumors in patients with a specific type of cancer before surgery, and it worked well for many of them.
Methodology
Patients with locally advanced non-metastatic GIST were treated with imatinib and then assessed for surgical resection based on their response.
Potential Biases
Selection bias may occur as patients were chosen for surgery based on clinical judgment rather than random assignment.
Limitations
The study is retrospective and lacks randomization, which may introduce bias in patient selection for surgery.
Participant Demographics
Median age was 65.5 years, with 64% male participants.
Statistical Information
P-Value
0.0318 for PFS, 0.0217 for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website